Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination With Bendamustine vs. Bendamustine Alone in Patients With Relapsed Chronic Lymphocytic Leukemia

NCT01188681 is registered in ClinicalTrials.gov with Aptevo Therapeutics as lead sponsor.

NCT NCT01188681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01188681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination With Bendamustine vs. Bendamustine Alone in Patients With Relapsed Chronic Lymphocytic Leukemia
Lead sponsor
Aptevo Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2010
Completion date
December 31, 2014
Enrollment
79 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll)